Virtual Library
Start Your Search
H. Mo
Author of
-
+
P3.01 - Poster Session/ Treatment of Advanced Diseases – NSCLC (ID 208)
- Event: WCLC 2015
- Type: Poster
- Track: Treatment of Advanced Diseases - NSCLC
- Presentations: 1
- Moderators:
- Coordinates: 9/09/2015, 09:30 - 17:00, Exhibit Hall (Hall B+C)
-
+
P3.01-061 - A Prognostic Model for Platinum-Doublet Regimens as Second-Line Chemotherapy in Advanced Non-Small-Cell Lung Cancer (NSCLC) Patients (ID 1228)
09:30 - 09:30 | Author(s): H. Mo
- Abstract
Background:
Poor prognosis of advanced non-small-cell lung cancer (NSCLC) patients and the promising therapeutic effect of platinum urge the oncologists to evaluate the role of platinum-doublet as second-line chemotherapy and establish the definition of platinum sensitivity in NSCLC.
Methods:
We retrospectively analyzed 364 advanced NSCLC patients who received platinum-doublet regimens as second-line chemotherapy after platinum-based first-line treatment. Patients were divided into four groups by their time-to-progression (TTP) after first-line chemotherapy: 0-3, 4-6, 7-12, and >12months group, respectively. Treatment efficacy of patients’ overall survival (OS), progression-free survival (PFS) and response rate (RR), as well as treatment-related toxicity, were compared among the four groups. A prognosis score system was established by Cox proportional hazard model.
Results:
All patients had Eastern Cooperative Oncology Group performance status (ECOG PS) of 0-1. As part of the platinum-doublet regimen,145(39.8%) patients received taxol, 81(22.3%) received gemcitabine, 99(27.2%) received pemetrexed, 32(8.8%) received vinorelbine, 4(1.1%) received etoposide, and 3(0.8%) received irinotecan. The most frequent grade 3/4 toxicity was neutropenia (20.1%) and nausea/vomiting (3.3%).The median follow-up time was 11.0 months. Patients with TTP> 12 months had significant longer survival than the rest of the group after second-line platinum-rechallenge (HR, 0.809; 95% CI: 0.703-0.931;P=0.003).Prognostic score (TAF score) was calculated by adding 1 point each for any of the following: TTP>12 months, age≤60 years, and female, all of which were independent prognostic factors for patient survival (P=0.015, P=0.002, P=0.012, respectively). Median OS were equal to 25.0, 16.0 and 11.0 months for best (2-3 points), intermediate (1 point) and worst (0 point) category, respectively (P<0.0001, Figure 1). Figure 1 Kaplan–Meier curves of overall survival according to patients’ TAF Score. After second-line platinum-based chemotherapy, patients with a TAF Score of 2-3 had significant better survival than those scored 0 or 1 (P<0.0001). Figure 1
Conclusion:
A TAF score of 2 or 3 points indicates a good prognosis if advanced NSCLC patients received platinum-rechallenge after disease progression.
